Synthace Limited

Synthace Limited specializes in providing advanced software solutions tailored for discovery biology teams, enhancing the efficiency of experimentation in assay development through innovative tools and expert support. Founded in 2011 in London, UK, Synthace Limited focuses on revolutionizing experimental workflows for life sciences. The company has successfully raised GBP 24. 98 mn in its Series C funding round on November 12, 2021, co-led by Horizons Ventures and Sofinnova Partners, contributing to its total amount raised of GBP 24.

98 mn and a current valuation of GBP 109. 29 mn. The company was co-founded by Chris Grant and Markus Gershater, with Guy Levy-Yurista serving as CEO. Synthace provides a sophisticated software platform and expert services specifically designed for discovery biology teams, emphasizing enhanced efficiency in assay development.

Their offerings include tools for designing and executing multifactorial experiments, which allow scientists to explore a wide range of variables while optimizing research outcomes. By combining software capabilities with on-site support from experienced Field Application Scientists, Synthace aims to streamline workflows and improve experimental throughput for clients primarily in pharmaceutical, biotech, and academic institutions across North America, Europe, and parts of Asia. In 2023, Synthace reported a revenue of GBP 2,413,180. 90 with an EBITDA of GBP -13,226,321, reflecting the company's ongoing investment in its technology and services.

Synthace Limited plans to utilize its recent Series C funding to broaden access to its research and development technology and expand its senior leadership team in the US. The company is focused on developing new products to enhance its platform, although specific release dates have not been disclosed. Additionally, Synthace aims to penetrate new geographic markets to strengthen its presence in the life sciences sector.